Nasal spray options include steroids (e.g. Flonase, Nasacort), which are best for allergies and long-term inflammation but ...

Unlike the hay fever many experience in the spring and summer months, which is an allergic reaction to pollen, winter hay ...

Hikma expected another year of growth in 2025, forecasting revenue growth of four to six per cent after a strong 2024.

However, Hikma’s core EBIT for the year stood at $719 million, with a margin of 22.8%, slightly below the consensus estimate of 23.4%. Hikma’s 2H24 results showed a 3% sales beat, primarily driven by ...

Hikma Pharmaceuticals PLC posted robust financial results for 2024, with revenue climbing 9% to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released Wednesday. The ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

It's allergy season in Arizona. Here's everything to know, including what is causing your allergies, common seasonal allergy ...

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” ...